BLCO icon

Bausch + Lomb

16.41 USD
-0.23
1.38%
At close Feb 14, 4:00 PM EST
After hours
16.41
+0.00
0.00%
1 day
-1.38%
5 days
2.31%
1 month
-4.81%
3 months
-16.15%
6 months
6.49%
Year to date
-8.83%
1 year
14.84%
5 years
-17.95%
10 years
-17.95%
 

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,300

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

138% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 16

75% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]

24% more funds holding

Funds holding: 89 [Q2] → 110 (+21) [Q3]

23% more capital invested

Capital invested by funds: $593M [Q2] → $729M (+$136M) [Q3]

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

0.88% less ownership

Funds ownership: 11.62% [Q2] → 10.74% (-0.88%) [Q3]

70% less call options, than puts

Call options by funds: $2.68M | Put options by funds: $8.83M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
10%
upside
Avg. target
$21
27%
upside
High target
$24
46%
upside

7 analyst ratings

positive
43%
neutral
43%
negative
14%
RBC Capital
Douglas Miehm
65% 1-year accuracy
13 / 20 met price target
34%upside
$22
Outperform
Maintained
29 Jan 2025
Stifel
Thomas Stephan
39% 1-year accuracy
7 / 18 met price target
10%upside
$18
Hold
Maintained
29 Jan 2025
Wells Fargo
Larry Biegelsen
63% 1-year accuracy
30 / 48 met price target
46%upside
$24
Overweight
Maintained
16 Jan 2025
B of A Securities
Craig Bijou
43% 1-year accuracy
3 / 7 met price target
10%upside
$18
Underperform
Reinstated
12 Dec 2024
HC Wainwright & Co.
Yi Chen
39% 1-year accuracy
62 / 159 met price target
40%upside
$23
Buy
Reiterated
12 Dec 2024

Financial journalist opinion

Neutral
Accesswire
1 week ago
Bausch Health Provides Update on Strategic Alternatives
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation.
Bausch Health Provides Update on Strategic Alternatives
Negative
Benzinga
1 month ago
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 150 points on Tuesday.
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Neutral
Seeking Alpha
3 months ago
Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
3 months ago
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
Zacks Investment Research
3 months ago
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago.
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates
Positive
The Motley Fool
4 months ago
Why Bausch + Lomb Stock Soared by Over 7% on Monday
It was quite a busy and eventful day for the company.
Why Bausch + Lomb Stock Soared by Over 7% on Monday
Positive
Investopedia
4 months ago
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid
Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company.
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid
Positive
Benzinga
4 months ago
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors.
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Positive
Zacks Investment Research
5 months ago
Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?
Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?
Positive
Schwab Network
5 months ago
Overlooked Stock: BLCO
Bausch + Lomb (BLCO) closed on a 52-week high following reports of the company planning to sell itself. George Tsilis explains why this led to a rally for the medical services company.
Charts implemented using Lightweight Charts™